Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
2022 · Gynecologic Oncology · 35 citations
https://doi.org/10.1016/j.ygyno.2022.05.021
T
Tobias M.P. Hartwich
Yale University(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
102
Papers
1.0K
Citations
13
h-index
16
i10-index
Tobias M.P. Hartwich is an academic researcher from Yale University. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & HER2/EGFR in Cancer Research & Genetic factors in colorectal cancer. The author has an h-index of 13, co-authored 87 publications.
ORCID: 0000-0002-2854-2894Papers by this author
worksTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
2023 · Gynecologic Oncology · 23 citations
https://doi.org/10.1016/j.ygyno.2022.12.018
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells
2020 · Oncogenesis · 13 citations
https://doi.org/10.1038/s41389-020-0243-y
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
2023 · Gynecologic Oncology Reports · 9 citations
https://doi.org/10.1016/j.gore.2023.101218
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
2024 · Clinical & Experimental Metastasis · 9 citations
https://doi.org/10.1007/s10585-024-10297-z
<i>In Vivo</i> and <i>In Vitro</i> Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
2023 · Molecular Cancer Therapeutics · 8 citations
https://doi.org/10.1158/1535-7163.mct-23-0126
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat